These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2727957)

  • 1. Neutralization of dermatan sulfate in vitro and in vivo by protamine sulfate and polybrene.
    Sié P; Cremers B; Dupouy D; Caranobe C; Dol F; Boneu B
    Thromb Res; 1989 Apr; 54(1):63-74. PubMed ID: 2727957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of heparin, protamine and polybrene on the time integral of thrombin generation (endogenous thrombin potential).
    Rotteveel RC; Roozendaal KJ; Weijers RN; Eijsman L
    Haemostasis; 1996; 26(1):1-10. PubMed ID: 8698272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retroviral vector-mediated gene transfer into keratocytes: in vitro effects of polybrene and protamine sulfate.
    Seitz B; Baktanian E; Gordon EM; Anderson WF; LaBree L; McDonnell PJ
    Graefes Arch Clin Exp Ophthalmol; 1998 Aug; 236(8):602-12. PubMed ID: 9717657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of thrombin/antithrombin III reaction in the presence of protamine or polybrene.
    Oshima G
    Thromb Res; 1988 Sep; 51(6):565-74. PubMed ID: 3187966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE; Thomas DP
    Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro neutralization of heparin in plasma prior to the activated partial thromboplastin time test: an assessment of four heparin antagonists and two anion exchange resins.
    Cumming AM; Jones GR; Wensley RT; Cundall RB
    Thromb Res; 1986 Jan; 41(1):43-56. PubMed ID: 3961726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep.
    Montalescot G; Zapol WM; Carvalho A; Robinson DR; Torres A; Lowenstein E
    Circulation; 1990 Nov; 82(5):1754-64. PubMed ID: 2171807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics.
    Sugiyama T; Itoh M; Ohtawa M; Natsuga T
    Thromb Res; 1992 Oct; 68(2):119-29. PubMed ID: 1335615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
    Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
    Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new principle in heparin assaying based on partial neutralization of heparin with polybrene.
    Talstad I
    Thromb Res; 1980 May 1-15; 18(3-4):485-91. PubMed ID: 7414543
    [No Abstract]   [Full Text] [Related]  

  • 11. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
    Diness V; Ostergaard PB
    Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
    Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study on the erythrocyte aggregating properties of polybrene and protamine sulphate.
    Inglis G; Sheridan R
    Transfusion; 1978; 18(1):84-8. PubMed ID: 625786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of heparin and related polysaccharides.
    Boneu B; Dol F; Caranobe C; Sie P; Houin G
    Ann N Y Acad Sci; 1989; 556():282-91. PubMed ID: 2544127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of dermatan sulfate in the rabbit after intravenous injection.
    Dol F; Houin G; Dupouy D; Cadroy Y; Caranobe C; Gabaig AM; Mardiguian J; Sié P; Boneu B
    Thromb Haemost; 1988 Apr; 59(2):255-8. PubMed ID: 3388296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
    Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
    J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of plasma heparin by polybrene neutralization.
    Nash PV; Bjornsson TD
    Anal Biochem; 1984 May; 138(2):319-23. PubMed ID: 6742408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of in vitro thrombin generation after neutralization of heparin.
    Hardy M; Douxfils J; Morimont L; Didembourg M; Carlo A; de Maistre E; Lecompte T; Mullier F
    Int J Lab Hematol; 2022 Feb; 44(1):168-176. PubMed ID: 34582127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of heparin and LMW heparin on hemostasis.
    Hirsh J; Buchanan MR
    Thromb Res Suppl; 1991; 14():11-7. PubMed ID: 1658966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of two heparin-neutralizing agents: protamine and polybrene.
    GODAL HC
    Scand J Clin Lab Invest; 1960; 12(4):446-57. PubMed ID: 13706163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.